Dian Diagnostics Group Co Ltd
SZSE:300244
EV/FCFF
Enterprise Value to FCFF
Enterprise Value to Free Cash Flow To Firm (EV/FCFF) ratio is a valuation multiple that compares the value of a company, debt included, to the amount of free cash flow available for all stakeholders. This metric is very similar to the EV/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
Market Cap | EV/FCFF | ||||
---|---|---|---|---|---|
CN |
Dian Diagnostics Group Co Ltd
SZSE:300244
|
9B CNY | 7.8 | ||
US |
C
|
Cigna Group
XMUN:CGN
|
89B EUR | 11.7 | |
US |
Cigna Corp
NYSE:CI
|
94.5B USD | 11.5 | ||
US |
CVS Health Corp
NYSE:CVS
|
71.9B USD | 14.6 | ||
US |
Laboratory Corporation of America Holdings
NYSE:LH
|
17.4B USD | 29.9 | ||
DE |
Fresenius SE & Co KGaA
XETRA:FRE
|
15.6B EUR | 8.6 | ||
US |
Quest Diagnostics Inc
NYSE:DGX
|
16B USD | 20.5 | ||
DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
11.8B EUR | 11 | |
DE |
Fresenius Medical Care AG
XMUN:FME
|
11.8B EUR | 11 | ||
US |
DaVita Inc
NYSE:DVA
|
12.4B USD | 22.8 | ||
US |
Oak Street Health Inc
NYSE:OSH
|
9.5B USD | -25.2 |
EV/FCFF Forward Multiples
Forward EV/FCFF multiple is a version of the EV/FCFF ratio that uses forecasted free cash flow to firm for the EV/FCFF calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to firm forecasts for 1, 2, and 3 years ahead, respectively.